Mumbai: Pharma major Lupin Limited (Lupin) announced today the completion of a PAI inspection (Prior Approval Inspection) carried out by the US FDA at its Aurangabad manufacturing facility with one 483 observation. The observation was procedural in nature and corrected during the inspection itself.

About Lupin Limited

Lupin is an innovation led transnational pharmaceutical company developing and delivering a wide range of branded & generic formulations, biotechnology products and APIs globally. The Company is a significant player in the Cardiovascular, Diabetology, Asthma, Pediatric, CNS, GI, Anti-Infective and NSAID space and holds global leadership position in the Anti-TB segment.

Lupin is the 4^th and the 6^th largest generics pharmaceutical company by market capitalization and revenues globally (March 31^st, 2017, Bloomberg). The Company is the 4^th largest pharmaceutical player in the US by prescriptions (Quintiles IMS MAT March 2017); the 2^nd largest Indian pharmaceutical company by global revenues; the 6^th largest generic pharmaceutical player in Japan and the 6^th largest company in Indian Pharmaceutical Market (Quintiles IMS MAT March 2017).

For the financial year ended 31^st March, 2017, Lupin’s Consolidated sales and Net profit stood at Rs. 171,198 million (USD 2.55 billion) and Rs. 25,575 million (USD 381 million) respectively. Please visit http://www.lupin.com  for more information. You could also follow us on Twitter – www.twitter.com/lupinlimited

CIN: L24100MH1983PLC029442 Registered Office: Lupin Ltd, 3rd Floor, Kalpataru Inspire, Off Western Express Highway, Santacruz (East), Mumbai 400 055.

For further information or queries please contact –

Pooja Thakran
VP – Corporate Communications
Ph: +91-22-66402531 / 9811665000
Email: poojathakran@lupin.com

or

Arvind Bothra
Head – Investor Relations and M&A
Ph: +91-22-66402137
Email: arvindbothra@lupin.com